Who are QLM3003's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Combination 1, D-Col Personal Hygiene Convenience Kit, PF-06882961 (Cohorts 1 and 2), Entecavir+Fuzheng Huayu+TCM Granule, PF-07104091 monotherapy dose expansion (ovarian), ECx1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/qlm3003.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

QLM3003 — Competitive Intelligence Brief

QLM3003 (QLM3003) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: small molecule. Area: Cardiovascular.

phase 3 small molecule molecular target Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

QLM3003 (QLM3003) — Qilu Pharmaceutical Co., Ltd.. QLM3003 is a small molecule drug that targets the molecular target.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
QLM3003 TARGET	QLM3003	Qilu Pharmaceutical Co., Ltd.	phase 3	small molecule	molecular target
Combination 1	combination-1	Pfizer	marketed	Combination therapy	Multiple molecular targets
D-Col Personal Hygiene Convenience Kit	col	Pfizer	marketed	not well-documented	various molecular targets
PF-06882961 (Cohorts 1 and 2)	pf-06882961-cohorts-1-and-2	Pfizer	marketed	pharmacological class	molecular target
Entecavir+Fuzheng Huayu+TCM Granule	Entecavir+Fuzheng Huayu+TCM Granule	ShuGuang Hospital	marketed	Nucleoside reverse transcriptase inhibitor + Traditional Chinese Medicine herbal combination	HBV reverse transcriptase (entecavir component); multiple herbal constituents with unclear specific molecular targets
PF-07104091 monotherapy dose expansion (ovarian)	pf-07104091-monotherapy-dose-expansion-ovarian	Pfizer	marketed	small molecule	[insert molecular target]
ECx1	ECx1	Oregon Health and Science University	marketed	small molecule	ECx1's molecular target is unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (small molecule class)

Pfizer · 5 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 4 drugs in this class
Jiangsu HengRui Medicine Co., Ltd. · 3 drugs in this class
Avalo Therapeutics, Inc. · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Cipla BioTec Pvt. Ltd. · 1 drug in this class
ChemRar Research and Development Institute, LLC · 1 drug in this class
Daewoong Pharmaceutical Co. LTD. · 1 drug in this class
Dilafor AB · 1 drug in this class
Daewon Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). QLM3003 — Competitive Intelligence Brief. https://druglandscape.com/ci/qlm3003. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab